Abstract 214P
Background
The rising incidence and mortality due to multiple myeloma (MM) is an alarming concern worldwide. Though, available chemotherapeutics possess the potential for treatment of MM, however, refractory and relapse condition in patients along with the associated side effects prompts to identify an effective treatment modality. Previously, our group reported myeloma-promoting effect of a chondroitin sulfate proteoglycan, Versican and showcased as an important target but the domain of this proteoglycan responsible for myeloma pathogenesis was not known. Hence, we assessed the effect of C-terminal domain (or G3 domain) of Versican in myeloma pathogenesis in vitro.
Methods
C-terminal (or G3) domain of Versican pertaining to 266 amino acids was commercially synthesized. This domain was supplemented in culture medium of myeloma cells (RPMI8226 & U266) at varied concentrations ranging from 100pM to 2000pM. Following treatment, effect of Versican C-terminal domain was investigated on cell proliferation, apoptosis, migration & invasion by suitable cell-based assays. Furthermore, the downstream signaling pathways affected by G3 domain of versican was identified by western blotting.
Results
The presence of Versican G3 domain in the extracellular milieu of cultured cells resulted in enhanced proliferation of myeloma cells. In addition, cell apoptosis was reduced while migratory and invading ability of myeloma cells potentiated when C-terminal domain of versican was added in the culture medium. All these effects of versican C-terminal domain were obtained due to the activation of FAK and STAT3 signaling cascades in multiple myeloma cells.
Conclusions
G3 (or C-terminal) portion of versican induced myeloma cell proliferation, migration and invasion of myeloma cells with simultaneous reduction in cell apoptosis via FAK/STAT3 signaling mechanism. These findings suggest the role of versican G3 domain as a plausible therapeutic target which could be tested further in myeloma xenograft models.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Funding
All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract